Microplastics are ubiquitous contaminants of marine ecosystems around the world and Antarctica is no exception. Microplastics can be influenced by sedimentary dynamics mainly on coastal areas where they are more abundant in Antarctica. This study evaluated microplastic contamination in beach environments from two Antarctic Specially Protected Areas, aiming to identify relationships between microplastic numbers and sedimentological parameters on beach sediments. Low numbers of microplastics were found (> 0.5 mm; fibers excluded) - one particle per sample in 4 of 15 samples analyzed - and there is no evidence of widespread contamination. Sedimentological parameters reveal differences between sampled environments, but low numbers of microplastics impaired statistical comparison. All sediment samples are coarse, denoting highenergy depositional environments that are likely little susceptible to microplastic accumulation. Microplastic contamination in the Antarctic coastal ecosystem is heterogeneous, and their detailed characterization assisted by a systematization of methods can improve the understanding of microplastics distribution patterns in the cold coastal ecosystem.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/0001-3765202320230283 | DOI Listing |
Alzheimers Dement
December 2024
Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China.
Background: Glucagon-like peptide 1 (GLP-1) is a peptide hormone that plays several physiological roles in treating diabetes and in protecting the brain. Recent clinical trials testing 4 different GLP-1 class drugs in phase 2 trials showed a clear correlation between neuroprotection and the ability to cross the BBB. Exenatide and Lixisenatide both showed excellent protective effects in patients Parkinson's disease (PD) and both drugs can readily cross the BBB.
View Article and Find Full Text PDFBackground: Clinical trial sponsors rely on research sites to identify and enroll appropriate study participants and to correctly and reliably assess symptom severity and function over the course of the trial. Low-recruiting sites represent a large financial and operational burden and may negatively impact trial success either by selecting inappropriate participants and/or high prevalence of data quality issues. We previously reported that >60% of sites in schizophrenia clinical trials recruited ≤5 participants.
View Article and Find Full Text PDFBackground: Alzheimer's Disease (AD) is the leading form of senile dementia, affecting ∼6 million Americans and having a national economic impact of $321 billion, numbers expected to double by 2050. The major pathological hallmarks of AD include Amyloid Beta (Aβ) plaques and Tau neurofibrillary tangles (NFT). The first goal of this research was to develop novel forms of carbon dots (CD) using various precursors.
View Article and Find Full Text PDFBackground: To improve clinical translatability of non-clinical in-vivo Alzheimer's disease (AD) models, a humanized APP knock-in mouse model (APP) was recently created (Xia, D. et al., 2022).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.
Background: Randomized placebo-controlled trials (RCTs) are the gold standard to evaluate efficacy of new drug treatments for Alzheimer's disease. For example, the United States FDA approved the brain amyloid-targeting drug lecanemab following CLARITY AD, Biogen and Eisai's Phase 3 RCT. However, recruiting enough participants for a high-powered and demographically representative trial is difficult and expensive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!